David Parks

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

Michael Aboud, Chloe Orkin, Daniel Podzamczer et al. · The Lancet HIV · 2019 · 116 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Comparison of Topical Ciprofloxacin to Conventional Antibiotic Therapy in the Treatment of Ulcerative Keratitis

David Parks, Donald A. Abrams, Faith A. Sarfarazi et al. · American Journal of Ophthalmology · 1993 · 76 citations

Medicine, Dermatology, Pharmacotherapy +7

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health

Grace A. McComsey, Sergio Lupo, David Parks et al. · AIDS · 2017 · 57 citations · Full text

Pharmacy, Pharmacotherapy, Bone Metabolism +16

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

Jean van Wyk, Chloe Orkin, Rafael Rubio et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2020 · 50 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17